This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reed, J. A. Articles by Albino, A. P. Search for Related Content PubMed PubMed Citation Articles by Reed, J. A. Articles by Albino, A. P.

(American Journal of Pathology. 1999;155:549-555.)
© 1999 American Society for Investigative Pathology

Regular Articles

Divergent Cellular Differentiation Pathways during the Invasive Stage of Cutaneous Malignant Melanoma Progression

Jon A. Reed^*, Bridget Finnerty and Anthony P. Albino

From the Section of Dermatopathology,^*
Department of Pathology, Baylor College of Medicine, Houston, Texas; the Dermatopathology Division,
Department of Pathology, New York Presbyterian Hospital-Cornell Medical Center, New York, New York; and The American Health Foundation,
Valhalla, New York

Melanocytic nevus cells in the dermis adopt many morphological features of Schwann cells. These differentiation-related changes typically are not observed in melanomas. However, nevus cells do not fully recapitulate a Schwann cell phenotype, because they lack expression of mature myelin-associated proteins. In this study, melanocytic nevi and malignant melanomas were examined by immunohistochemistry for expression of low-affinity nerve growth factor receptor (p75NGFR), neural cell adhesion molecule (CD56/N-CAM), and growth-associated phosphoprotein-43 (GAP-43). These three proteins define the earliest stages of Schwann cell development but are not expressed in myelinated Schwann cells or normal melanocytes. p75NGFR was expressed in 25 of 25 (100%) and CD56/N-CAM and GAP-43 in 23 of 25 (92%) nevi, predominantly in type C nevus cells and nevic corpuscles. Most (84%) of the nevi expressed all three proteins. In primary invasive and metastatic melanoma, expression of each of the three proteins was limited to 20% of lesions but was not observed in any melanoma in situ (² P < 0.0001). None of the melanomas expressed all three proteins (ANOVA P < 0.0001). These data confirm and extend earlier studies by showing that terminal differentiation of melanocytes in the dermis recapitulates some aspects observed in the earliest stages of Schwann cell development and that invasive melanomas follow a divergent pathway. Studying these early differentiation events may help to identify specific defects in the relevant signaling pathways and establish tenable targets for therapy of advanced-stage melanoma.

This article has been cited by other articles:

				K. M. R. Bhat, N. Maddodi, C. Shashikant, and V. Setaluri Transcriptional regulation of human MAP2 gene in melanoma: role of neuronal bHLH factors and Notch1 signaling Nucleic Acids Res., August 11, 2006; 34(13): 3819 - 3832. [Abstract] [Full Text] [PDF]

				D. Fang, T. K. Nguyen, K. Leishear, R. Finko, A. N. Kulp, S. Hotz, P. A. Van Belle, X. Xu, D. E. Elder, and M. Herlyn A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas Cancer Res., October 15, 2005; 65(20): 9328 - 9337. [Abstract] [Full Text] [PDF]

				S. G. Slutsky, A. K. Kamaraju, A. M. Levy, J. Chebath, and M. Revel Activation of Myelin Genes during Transdifferentiation from Melanoma to Glial Cell Phenotype J. Biol. Chem., March 7, 2003; 278(11): 8960 - 8968. [Abstract] [Full Text] [PDF]

				A. K. Kamaraju, C. Bertolotto, J. Chebath, and M. Revel Pax3 Down-regulation and Shut-off of Melanogenesis in Melanoma B16/F10.9 by Interleukin-6 Receptor Signaling J. Biol. Chem., April 19, 2002; 277(17): 15132 - 15141. [Abstract] [Full Text] [PDF]

				D. Fang, J. Hallman, N. Sangha, T. E. Kute, J. A. Hammarback, W. L. White, and V. Setaluri Expression of Microtubule-Associated Protein 2 in Benign and Malignant Melanocytes : Implications for Differentiation and Progression of Cutaneous Melanoma Am. J. Pathol., June 1, 2001; 158(6): 2107 - 2115. [Abstract] [Full Text] [PDF]